2238821-33-3 Usage
Uses
Used in Pharmaceutical Industry:
(R)-tert-butyl (6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-yl)carbamate is used as a compound with potential pharmaceutical applications due to its antimicrobial, antifungal, and herbicidal properties. Its diverse biological activities make it a promising candidate for the development of new therapeutic agents.
Used in Agrochemical Industry:
In the agrochemical industry, (R)-tert-butyl (6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-yl)carbamate is used as a compound with potential applications in the development of new agrochemicals, particularly for its antimicrobial, antifungal, and herbicidal properties, which can contribute to the creation of more effective pesticides and fungicides.
Used in Research and Development:
(R)-tert-butyl (6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-yl)carbamate is used as a building block in the synthesis of other biologically active compounds for research and development purposes. Its specific stereochemistry and diverse biological activities make it a valuable tool in the discovery of new therapeutic agents or agrochemicals.
Check Digit Verification of cas no
The CAS Registry Mumber 2238821-33-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 2,2,3,8,8,2 and 1 respectively; the second part has 2 digits, 3 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 2238821-33:
(9*2)+(8*2)+(7*3)+(6*8)+(5*8)+(4*2)+(3*1)+(2*3)+(1*3)=163
163 % 10 = 3
So 2238821-33-3 is a valid CAS Registry Number.
2238821-33-3Relevant academic research and scientific papers
SULPHONAMIDES AND COMPOSITIONS THEREOF FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY
-
Page/Page column 532, (2019/05/10)
In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: wherein the variables shown in Formula AA can be as defined anywhere herein. Compounds AA are modulators of NLRP1 and/or NLRP3
CHEMICAL COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY
-
Paragraph 00822; 00831, (2018/08/12)
The present disclosure relates to novel sulfonylurea and sulfonyl thiourea compounds and related compounds and their use in treating a disease or condition responsive to modulation of cytokines such as IL-1β and IL-18, modulation of NLRP3 or inhibition of the activation of NLRP3 or related components of the inflammatory process.
